Clinical Trial

Safety and Dose-Response of Bletilla Formosana in Prediabetic Subjects

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study evaluates the safety and preliminary efficacy of Bletilla formosana (BF), a traditional herbal medicine, in adults with prediabetes. Prediabetes is a high-risk condition where blood sugar levels are elevated, often leading to type 2 diabetes. While lifestyle changes are the standard treatment, researchers are exploring herbal supplements as a complementary way to support metabolic health. Preclinical research has shown that BF possesses anti-inflammatory properties and may help regulate blood glucose. Participants in this study will be randomly assigned to receive either a high dose of BF, a low dose of BF, or a placebo (an inactive substance) for 12 weeks. The total study duration is approximately 24 weeks, involving four clinic visits for blood tests and safety monitoring to see how BF affects blood sugar markers and inflammation.
Trial Details
NCT Number NCT07704944
Lead Sponsor Chang Gung Memorial Hospital
Collaborators: National Science and Technology Council
Conditions Prediabetes
Enrollment 94 participants
Start Date 2026-07-01
Primary Completion 2027-07-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-15